Insider Buying: ChemoCentryx Director Buys 10,000 Shares of Stock (CCXI)
ChemoCentryx (NASDAQ:CCXI) Director Joseph Feczko bought 10,000 shares of ChemoCentryx stock on the open market in a transaction that occurred on Friday, September 13th. The stock was purchased at an average price of $6.03 per share, for a total transaction of $60,300.00. Following the purchase, the director now directly owns 10,000 shares in the company. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
Separately, analysts at JPMorgan Chase & Co. downgraded shares of ChemoCentryx (NASDAQ:CCXI) from an “overweight” rating to a “neutral” rating in a research note to investors on Tuesday, September 10th. They now have a $7.00 price target on the stock, down previously from $11.00.
Shares of ChemoCentryx (NASDAQ:CCXI) traded down 3.23% during mid-day trading on Monday, hitting $5.99. The stock had a trading volume of 627,833 shares. ChemoCentryx has a 52 week low of $5.28 and a 52 week high of $14.96. The stock has a 50-day moving average of $10.44 and a 200-day moving average of $12.61. The company’s market cap is $256.6 million.
ChemoCentryx (NASDAQ:CCXI) last released its earnings data on Monday, August 12th. The company reported ($0.23) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.28) by $0.05. The company had revenue of $1.90 million for the quarter, compared to the consensus estimate of $1.48 million. During the same quarter in the prior year, the company posted ($0.30) earnings per share. Analysts expect that ChemoCentryx will post $-1.03 EPS for the current fiscal year.
ChemoCentryx is a biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.